Tisagenlecleucel: all 42 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaRecruitingNCT07676877Phase 1
• CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for LupusRecruitingNCT06839976Phase 1/2
• CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and LymphomaRecruitingNCT06101381Phase 1/2
• Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
• Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 3
• CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingNCT03896854Phase 1/2
• Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedNCT05075603Phase 1Results posted
• Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04225676Phase 2Results posted
• MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive, not recruitingNCT03642626Phase 2Results posted
• Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma PatientsCompletedNCT03610724Phase 2Results posted
• Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaCompletedNCT03568461Phase 2Results posted
• Phase III B in Acute Lymphoblastic LeukemiaCompletedNCT03123939Phase 3Results posted
• CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALLTerminatedNCT02935543Phase 2Results posted
• Study of Efficacy and Safety of CTL019 in Adult DLBCL PatientsCompletedNCT02445248Phase 2Results posted
• Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02435849Phase 2Results posted
• Study of Efficacy and Safety of CTL019 in Pediatric ALL PatientsCompletedNCT02228096Phase 2Results posted
• Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02030847Phase 2Results posted
• Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ LymphomasCompletedNCT02030834Phase 2Results posted
• Dose Optimization Trial of CD19 Redirected Autologous T CellsCompletedNCT01747486Phase 2Results posted
• Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and LymphomaCompletedNCT01626495Phase 1/2Results posted
• CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to ChemotherapyCompletedNCT01029366Phase 1Results posted
• A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular LymphomaActive, not recruitingNCT05888493Phase 3
• A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruitingNCT05460533Phase 2
• Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to TherapyActive, not recruitingNCT04778579Phase 2
• Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)WithdrawnNCT04456023Phase 2
• Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
• TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin LymphomaTerminatedNCT04161118Phase 2
• Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALLWithdrawnNCT04156659Phase 2
• Tisagenlecleucel In Primary CNS LymphomaCompletedNCT04134117Phase 1
• Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsActive, not recruitingNCT03876769Phase 2
• Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma PatientsTerminatedNCT03876028Phase 1
• Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma PatientsCompletedNCT03630159Phase 1
• Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaWithdrawnNCT03628053Phase 3
• The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell LymphomaStatus unknownNCT03101709Phase 1
• CART-19 Cells For MRD Positive CD19+ ALLStatus unknownNCT03027739Phase 2/3
• Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release SyndromeCompletedNCT02906371Phase 1
• Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic LeukemiaStatus unknownNCT02810223Phase 1
• Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)TerminatedNCT02640209Early Phase 1
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
• Study of Efficacy and Safety of CTL019 in Adult ALL PatientsWithdrawnNCT02167360Phase 2
• CART-19 for Multiple MyelomaCompletedNCT02135406Phase 1
• Allo CART-19 ProtocolTerminatedNCT01551043Phase 1

← Tisagenlecleucel overview